March 30, 2023
Boehringer Ingelheim Chairman and CEO Hubertus von Baumbach Boehringer Ingelheim enjoyed growth of over 5% in its Japanese human pharma business in 2022, primarily driven by its SGLT2 inhibitor Jardiance (empagliflozin) and its idiopathic pulmonary fibrosis (IPF) treatment Ofev (nintedanib)...read more